Antibody-Drug Conjugates (ADCs) represent one of the most powerful and complex classes of cancer therapies ever developed – combining the precision of a monoclonal antibody with the potency of a cytotoxic payload.

Their multi-step, hazardous manufacturing process has made specialist ADC CDMO manufacturing one of the fastest-growing and most technically demanding segments in pharmaceutical outsourcing – and a critical strategic priority for both large pharma and emerging biotech sponsors.

The global ADC contract manufacturing market reached an estimated USD 11.08 billion in 2026 and is projected to expand to approximately USD 29.65 billion by 2035, at a CAGR of 11.56%, according to Towards Healthcare (2026).

The market is expanding steadily, fuelled by rising oncology therapies, expanding clinical pipeline, sustained commercial revenue from approved products, increasing R&D investment from both large pharma and emerging biotech, and the emergence of next-generation ADC technologies – including site-specific conjugation, bispecific ADCs, and novel payload classes – that demand more advanced CDMO platforms.

The availability of CDMOs that genuinely understand protein engineering, conjugation technologies, and next-generation ADC formats is far more limited than general purpose biologics capacity – and that scarcity is what positions specialist CDMOs as strategic partners rather than commodity suppliers.

The complexity of ADCs creates several manufacturing challenges. Traditionally, producing an ADC required multiple CDMOs, multiple quality systems, multiple technology transfers, and multiple regulatory inspections
– across different sites, different countries, different standards.